9 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
25 Apr 23
Results of Operations and Financial Condition
4:31pm
BioTherapeutics
PEACE Baseline Demographics Demographic Characteristic Pegzilarginase n=21 Placebo n=11 Overall N=32 Age at Enrollment, y Mean (SD) 9.6
PRE 14A
SYRE
Spyre Therapeutics Inc.
7 Apr 23
Preliminary proxy
4:02pm
Asian
Hispanic or Latino
Native Hawaiian or Pacific Islander
White
Two or More Races or Ethnicities
LGBTQ+
Did Not Disclose Demographic Background
8-K
EX-99.2
SYRE
Spyre Therapeutics Inc.
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
Demographic Characteristic Pegzilarginase n=21 Placebo n=11 Overall N=32 Age at Enrollment, y Mean (SD) 9.6 (6.16) 12.9 (6.77) 10.7 (6.47) Range 2-28 5
8-K
EX-99.1
dtikzd 5ahtlcekob2
6 Sep 22
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
v74zzayqjg4la 44bd
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
8-K
EX-99.2
namq9 m0s
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
- Prev
- 1
- Next